A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Thermo Fisher – Next-Generation Nano, Capillary- & Micro-Flow LC Systems Enhance Productivity & Performance

Thermo Fisher – Principal investigators, laboratories, and proteomics researchers in academia, biopharma, and contract research organizations can now benefit from an all-in-one nano-, capillary- and micro-flow liquid chromatography (LC) system.

Designed for high sensitivity LC-mass spectrometry (LC-MS) applications, technical capabilities and seamless integration with Thermo Scientific PepMap Neo Columns and Thermo Scientific mass-spectrometry portfolio, the new Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns help users overcome limitations of existing low-flow LC instruments.

“Low-flow LC users are limited by technical capacity and a high level of expertise required for system operation,” said Kent Davidson, vice president, and general manager, high-performance chromatography solutions, Thermo Fisher Scientific. “The Vanquish Neo UHPLC System and PepMap Neo Columns allow for long-term operation at maximum performance levels without compromise. Enhanced ease-of-use and increased versatility enable users to push science forward.”

Professor Bernhard Kuster, Technical University Munich, said, “The Vanquish Neo UHPLC System will transform how scientists perform proteomics studies by providing the long-term robustness and flow-range versatility required for deep and fast LC-MS profiling of thousands of proteomes, while coupled with PepMap Columns and high-resolution accurate mass (HRAM) systems.”

The new Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns deliver application flexibility and robust analytical performance at flow rates from 1 nL/min to 100 µL/min up to 1500 bar. Novice and expert LC-MS users will enjoy accelerated productivity, reduced method overhead time, and long-term operation essential for 24/7 large sample cohort analysis.

Users of the Vanquish Neo UHPLC System and PepMap Neo Columns benefit from:

  • Excellent separation performance, column-to-column reproducibility, and simple operation.
  • Seamless integration with the comprehensive portfolio of Thermo Scientific mass spectrometers.
  • Enhanced quantitation through high-injection volume linearity, precision and accuracy.
  • Negligible system carryover with automated wash routines.
  • System monitoring and control with automated procedures and guided maintenance routines through the Thermo Scientific Vanquish User Interface.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy